Merck’s targeted cancer drug sac-TMT extends survival in endometrial cancer, prompting US priority review and potential approval by 2027. Merck's sacituzumab tirumotecan significantly extends survival in advanced endometrial cancer, earning a U.S. health regulator's priority review based on trial results. Merck's investigational endometrial cancer drug sacituzumab tirumotecan, also known as sac-TMT, increased survival rate in patients by at least 32%.